Diabetes mellitus is associated with impaired response to antiviral therapy in chronic hepatitis C infection

Digestive Diseases and Sciences

Volumn 54, Issue 12, 2009, Pages 2699-2705

  Elgouhari, Hesham M ^a   Zein, Claudia O ^b   Hanouneh, Ibrahim ^b   Feldstein, Ariel E ^b   Zein, Nizar N ^b  

^a UNIVERSITY OF SOUTH DAKOTA   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Diabetes mellitus; Hepatitis C infection; Insulin sensitizing agents; Sustained virologic response

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDEPRESSANT AGENT; ERYTHROPOIETIN; FILGRASTIN; INSULIN; INSULIN SENSITIZING AGENT; METFORMIN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; UNCLASSIFIED DRUG;

ADULT; AFRICAN AMERICAN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; CAUCASIAN; CLINICAL ASSESSMENT; CONTROLLED STUDY; DEPRESSION; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG WITHDRAWAL; ETHNICITY; FATIGUE; FATTY LIVER; FEMALE; GENOTYPE; GROUPS BY AGE; HEPATITIS C; HISTOLOGY; HUMAN; INFECTION; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; OBESITY; PATIENT IDENTIFICATION; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT FAILURE; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; CASE-CONTROL STUDIES; DIABETES MELLITUS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; INTERFERON ALFA-2A; INTERFERON ALFA-2B; LIVER CIRRHOSIS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; OHIO; POLYETHYLENE GLYCOLS; RETROSPECTIVE STUDIES; RIBAVIRIN; RISK ASSESSMENT; RISK FACTORS; RNA, VIRAL; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT FAILURE; VIRAL LOAD;

EID: 70450239924     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-008-0683-2     Document Type: Article

References (35)

1. ME Allison T Wreghitt CR Palmer, et al. 1994 Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population J Hepatol 21 1135 1139 10.1016/S0168-8278(05)80631-2 10.1016/S0168-8278(05)80631-2 1:STN:280:DyaK2M3htlGltA%3D%3D 7699240
2. S Caronia K Taylor L Pagliaro, et al. 1999 Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection Hepatology 30 1059 1063 10.1002/hep.510300416 10.1002/hep.510300416 1:CAS:528:DyaK1MXmslWgtb0%3D 10498660 (Pubitemid 29458297)
3. H Knobler R Schihmanter A Zifroni, et al. 2000 Increased risk of type 2 diabetes in non-cirrhotic patients with chronic hepatitis C virus infection Mayo Clin Proc 75 355 359 10.4065/75.4.355 1:STN:280:DC%2BD3c3isVGmtw%3D%3D 10761489
4. AL Mason JY Lau N Hoang, et al. 1999 Association of diabetes mellitus and chronic hepatitis C virus infection Hepatology 29 328 333 10.1002/hep.510290235 10.1002/hep.510290235 1:STN:280:DyaK1M7hvFeqsA%3D%3D 9918906 (Pubitemid 29088433)
5. SH Mehta FL Brancati MS Sulkowski, et al. 2001 Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States Hepatology 33 1554 10.1053/jhep.2001.0103306le01 10.1053/jhep.2001. 0103306le01 1:STN:280:DC%2BD3MzhvFahug%3D%3D 11391549
6. CO Zein C Levy A Basu, et al. 2005 Chronic hepatitis C and type II diabetes mellitus: a prospective cross-sectional study Am J Gastroenterol 100 48 55 10.1111/j.1572-0241.2005.40429.x 10.1111/j.1572-0241.2005.40429.x 15654780 (Pubitemid 41623268)
7. NN Zein AS Abdulkarim RH Wiesner, et al. 2000 Prevalence of diabetes mellitus in patients with end-stage liver cirrhosis due to hepatitis C, alcohol, or cholestatic disease J Hepatol 32 209 217 10.1016/S0168-8278(00)80065-3 10.1016/S0168-8278(00)80065-3 1:STN:280:DC%2BD3c7ntVWgsQ%3D%3D 10707860
8. R Simo A Lecube J Genesca, et al. 2006 Sustained virological response correlates with reduction in the incidence of glucose abnormalities in patients with chronic hepatitis C virus infection Diabetes Care 29 2462 2466 10.2337/dc06-0456 10.2337/dc06-0456 17065685 (Pubitemid 44912253)
9. V Ratziu M Munteanu F Charlotte, et al. 2003 Fibrogenic impact of high serum glucose in chronic hepatitis C J Hepatol 39 1049 1055 10.1016/S0168- 8278(03)00456-2 10.1016/S0168-8278(03)00456-2 1:CAS:528:DC%2BD3sXpt1egtbY%3D 14642625 (Pubitemid 37523779)
10. JA Davila RO Morgan Y Shaib, et al. 2005 Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study Gut 54 533 539 10.1136/gut.2004.052167 10.1136/gut.2004.052167 1:STN:280:DC%2BD2M7it1Chug%3D%3D 15753540 (Pubitemid 40403031)
11. GN Ioannou MF Splan NS Weiss, et al. 2007 Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis Clin Gastroenterol Hepatol 5 938 945 10.1016/j.cgh.2007.02.039 17509946 (Pubitemid 47127020)
12. HS Conjeevaram DE Kleiner JE Everhart, et al. 2007 Race, insulin resistance and hepatic steatosis in chronic hepatitis C Hepatology 45 80 87 10.1002/hep.21455 10.1002/hep.21455 1:CAS:528:DC%2BD2sXht1arsbo%3D 17187406 (Pubitemid 46144367)
13. R D'Souza CA Sabin GR Foster 2005 Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy Am J Gastroenterol 100 1509 1515 10.1111/j.1572-0241.2005.41403.x 10.1111/j.1572-0241.2005.41403.x 15984973 (Pubitemid 41032355)
14. S Dharancy M Malapel G Perlemuter, et al. 2005 Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection Gastroenterology 128 334 342 10.1053/j.gastro.2004.11.016 10.1053/j.gastro.2004.11.016 1:CAS:528:DC%2BD2MXitVemsLk%3D 15685545 (Pubitemid 40431087)
15. I Konishi N Horiike Y Hiasa, et al. 2007 Diabetes mellitus reduces the therapeutic effectiveness of interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C Hepatol Res 37 331 336 10.1111/j.1872-034X. 2007.00052.x 10.1111/j.1872-034X.2007.00052.x 1:CAS:528:DC%2BD2sXmtlSmsLw%3D 17441805 (Pubitemid 46605417)
16. M Romero-Gomez MV Del RJ Andrade, et al. 2005 Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients Gastroenterology 128 636 641 10.1053/j.gastro.2004.12.049 10.1053/j.gastro.2004.12.049 1:CAS:528:DC%2BD2MXivFWntL8%3D 15765399 (Pubitemid 40585366)
17. Y Shintani H Fujie H Miyoshi, et al. 2004 Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance Gastroenterology 126 840 848 10.1053/j.gastro.2003.11.056 10.1053/j.gastro.2003.11.056 1:CAS:528:DC%2BD2cXivFCisLw%3D 14988838 (Pubitemid 38298332)
18. CK Sung H She S Xiong, et al. 2004 Tumor necrosis factor-alpha inhibits peroxisome proliferator-activated receptor gamma activity at a posttranslational level in hepatic stellate cells Am J Physiol Gastrointest Liver Physiol 286 G722 G729 10.1152/ajpgi.00411.2003 10.1152/ajpgi.00411.2003 1:CAS:528: DC%2BD2cXkt1elsr4%3D 14656714 (Pubitemid 38506802)
19. JR Gavin III 1998 New classification and diagnostic criteria for diabetes mellitus Clin Cornerstone 1 1 12 10.1016/S1098-3597(98)90014-X 10.1016/S1098-3597(98)90014-X 10682169
20. AB Miller B Hoogstraten M Staquet, et al. 1981 Reporting results of cancer treatment Cancer 47 207 214 10.1002/1097-0142(19810101)47:1<207::AID- CNCR2820470134>3.0.CO;2-6 10.1002/1097-0142(19810101)47:1<207::AID- CNCR2820470134>3.0.CO;2-6 1:STN:280:DyaL3M7htFOltw%3D%3D 7459811 (Pubitemid 11167383)
21. KP Batts J Ludwig 1995 Chronic hepatitis. An update on terminology and reporting Am J Surg Pathol 19 1409 1417 1:STN:280:DyaK28%2FotlKkug%3D%3D 7503362
22. L Fartoux A Poujol-Robert J Guechot, et al. 2005 Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C Gut 54 1003 1008 10.1136/gut.2004.050302 10.1136/gut.2004.050302 1:CAS:528: DC%2BD2MXmsFKqtrs%3D 15951550 (Pubitemid 40873917)
23. M Romero-Gomez 2006 Insulin resistance and hepatitis C World J Gastroenterol 12 7075 7080 1:CAS:528:DC%2BD2sXls1GltA%3D%3D 17131467
24. MG Ghany DE Kleiner H Alter, et al. 2003 Progression of fibrosis in chronic hepatitis C Gastroenterology 124 97 104 10.1053/gast.2003.50018 10.1053/gast.2003.50018 12512034 (Pubitemid 36055343)
25. P Perumalswami DE Kleiner G Lutchman, et al. 2006 Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection Hepatology 43 780 787 10.1002/hep.21078 10.1002/hep.21078 16557550
26. MR Charlton PJ Pockros SA Harrison 2006 Impact of obesity on treatment of chronic hepatitis C Hepatology 43 1177 1186 10.1002/hep.21239 10.1002/hep.21239 16729327 (Pubitemid 43980094)
27. WM Lee JL Dienstag KL Lindsay, et al. 2004 Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon non-responders Control Clin Trials 25 472 492 10.1016/j.cct.2004.08. 003 10.1016/j.cct.2004.08.003 1:CAS:528:DC%2BD2cXotF2mtL0%3D 15465617 (Pubitemid 39299157)
28. BL Pearlman 2006 Hepatitis C virus infection in African Americans Clin Infect Dis 42 82 91 10.1086/498512 10.1086/498512 16323096 (Pubitemid 41832084)
29. MW Fried ML Shiffman KR Reddy, et al. 2002 Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 975 982 10.1056/NEJMoa020047 10.1056/NEJMoa020047 1:CAS:528:DC%2BD38Xnt12rtb0%3D 12324553
30. MP Manns JG McHutchison SC Gordon, et al. 2001 Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 958 965 10.1016/S0140-6736(01)06102-5 10.1016/S0140-6736(01)06102-5 1:CAS:528: DC%2BD3MXntF2qtb8%3D 11583749 (Pubitemid 32913521)
31. AJ Muir JD Bornstein PG Killenberg 2004 Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites N Engl J Med 350 2265 2271 10.1056/NEJMoa032502 10.1056/NEJMoa032502 1:CAS:528:DC%2BD2cXksVehtr4%3D 15163776 (Pubitemid 38669209)
32. MG Neuman LM Blendis NH Shear, et al. 2001 Cytokine network in non-responding chronic hepatitis C patients with genotype 1: role of triple therapy with interferon alpha, ribavirin, and ursodeoxycholate Clin Biochem 34 183 188 10.1016/S0009-9120(01)00213-2 10.1016/S0009-9120(01)00213-2 1:CAS:528:DC%2BD3MXltl2hurs%3D 11408015 (Pubitemid 32537669)
33. JC Pickup GD Chusney SM Thomas, et al. 2000 Plasma interleukin-6, tumour necrosis factor alpha and blood cytokine production in type 2 diabetes Life Sci 67 291 300 10.1016/S0024-3205(00)0062 10.1016/S0024-3205(00)00622-6 1:CAS:528:DC%2BD3cXksVOmt74%3D 10983873
34. G Taliani MC Badolato G Nigro, et al. 2002 Serum concentration of gammaGT is a surrogate marker of hepatic TNF-alpha mRNA expression in chronic hepatitis C Clin Immunol 105 279 285 10.1006/clim.2002.5288 10.1006/clim.2002.5288 1:CAS:528:DC%2BD38Xps12ktL0%3D 12498809 (Pubitemid 36016055)
35. NN Zein 2005 Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study J Hepatol 42 315 322 10.1016/j.jhep.2004.11.025 10.1016/j.jhep.2004.11.025 1:CAS:528: DC%2BD2MXhtlensr0%3D 15791697 (Pubitemid 40254244)